Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Tranexamic Acid (250mg) Tablet
Therapeutic Category
Gynecology and Fertility
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Traxlink 250 Tablet containing Tranexamic Acid is used for the management of excessive bleeding conditions. It helps stabilize blood clots and reduce abnormal bleeding episodes.
Tranexamic acid works as an antifibrinolytic agent that prevents breakdown of blood clots, thereby helping control bleeding effectively in clinical conditions.
The tablet is widely prescribed in gynecology and surgical practice for bleeding disorders and heavy menstrual bleeding, leading to consistent prescription demand.
With increasing awareness of bleeding management therapies and growing demand for effective hemostatic treatments, this product offers strong business potential for retailers and distributors. Its clinical importance, broad therapeutic use, and steady market demand make it a reliable product for growth in the hemostatic segment.
Some patients may experience nausea, vomiting, diarrhea, abdominal discomfort, or dizziness. Rarely, visual disturbances or risk of blood clot formation may occur.
Traxlink 250 Tablet is indicated for heavy menstrual bleeding (menorrhagia), bleeding disorders, nosebleeds (epistaxis), dental bleeding, and other conditions associated with excessive or abnormal bleeding. It helps reduce blood loss and stabilize clotting.
This medicine should be used under medical supervision. Use cautiously in patients with a history of thromboembolic disorders. Do not exceed the recommended dose.
Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.
Composition : Tranexamic Acid (500mg)
Composition : Tranexamic Acid (500mg) Injection
Composition : Tranexamic Acid (500mg) + Mefenamic Acid (250mg)
Composition : Tranexamic Acid (250mg) + Glutathione (50mg)
Composition : Tranexamic Acid (250mg) + Ethamsylate (250mg)
Composition : Ethinyl Estradiol (0.03mg) + Levonorgestrel (0.15mg)
Composition : Ethinyl Estradiol (0.03mg) + Desogestrel (0.15mg)
Composition : Ethinyl Estradiol (0.03mg) + Dienogest (2mg)
Composition : Ethinyl Estradiol (0.03mg) + Drospirenone (3mg)
Composition : Ondansetron (8 mg) MD
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Traxlink 250 Tablet has strong demand in the gynecology, bleeding-control, and surgical-care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on women’s health and general medicine portfolios.
Medical distributors and agencies can benefit from consistent demand for management of heavy menstrual bleeding (menorrhagia), abnormal uterine bleeding, bleeding after dental procedures, trauma-related bleeding, and post-surgical bleeding control. Tranexamic Acid 250mg helps reduce excessive bleeding by preventing breakdown of blood clots This strengthens a reliable gynecology and hemostatic-care portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Traxlink 250 Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from strong gynecologist and physician prescriptions, high demand in women’s health segment, seasonal usage patterns, reliable supply chain support, and good margins in hemostatic medicines.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.